Company news
Guangxi Wuzhou Zhongheng Group Co., Ltd. Class A (SSE:600252) news
Guangxi Wuzhou Zhongheng Group Co., Ltd. Class A news releases on 6ix. Latest, Dec 31, 2025: Announcement on Change of Financial Advisor for Continuous…
Press releases — page 2
Announcement on Change of Financial Advisor for Continuous Supervision
December 30, 2025
Announcement on Resolutions of the 35th Meeting of the 10th Board of Directors
December 29, 2025
Announcement on the Implementation of Repurchase and Cancellation of Equity Incentive Restricted Stocks
December 21, 2025
Announcement on Renewing Engagement of Accounting Firm for 2025
December 12, 2025
Announcement on Holding Sub-subsidiary Obtaining Notice of Approval for Drug Clinical Trials
December 4, 2025
Announcement on Internal Equity Adjustment of the Controlling Shareholder and Completion of Share Transfer by the Controlling Shareholder
November 3, 2025
Announcement on Resolutions of the 32nd Meeting of the 10th Board of Directors
October 30, 2025
Announcement on Convening the 2025 Semi-annual Performance Briefing
October 9, 2025
Announcement on Partial Shares for Cancellation and Reduction of Registered Capital and Notice to Creditors
September 29, 2025
Announcement on Internal Equity Adjustment of the Controlling Shareholder and the Proposed Change of the Controlling Shareholder
September 26, 2025
Announcement on Holding Subsidiary Providing Guarantee for Financing Credit to Another Controlling Subsidiary
September 22, 2025
Announcement on Holding Subsidiary Obtaining Drug Registration Certificate
September 17, 2025
Notice on Convening the 2nd Extraordinary General Meeting in 2025
September 12, 2025
Announcement on Resolutions of the 30th Meeting of the 10th Board of Directors
August 29, 2025
Announcement on Implementation Result of Shares Repurchase and Share Changes
August 26, 2025
Announcement on Holding Subsidiary Providing Guarantee for Financing Credit to Its Wholly-Owned Subsidiary
August 21, 2025
Announcement on Acquisition of a Drug Technology (Patent Right) for the Treatment of Chronic Heart Failure by a Wholly-owned Subsidiary and Signing of the Technology (Patent Right) Transfer Agreement
August 4, 2025
Announcement on Progress in Repurchasing Shares through Call Auction in 2025
August 1, 2025
Indicative Announcement on Proposed Changes in Equity Structure of Controlling Shareholder
July 28, 2025
Announcement on Resignation of Independent Director Due to 6-Year Term Completion
July 25, 2025
Announcement on Repurchasing 3% of the Company's Share Capital through Call Auction in 2025 and Repurchase Progress
July 18, 2025